C. Marin et al., LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats, SYNAPSE, 42(1), 2001, pp. 40-47
To evaluate the possible involvement of glutamate AMPA receptor-mediated me
chanisms in levodopa-induced motor fluctuations, we investigated the effect
s of LY293558, a competitive AMPA receptor antagonist, on levodopa-induced
motor alterations in rats with unilateral 6-OHDA lesion. Acute and chronic
administration of LY293558 was studied to evaluate the possible reversion o
r prevention of these levodopa effects. In the first set of experiments, ra
ts were treated with levodopa (25 mg/kg with benserazide, twice daily, i.p.
) for 22 days and on day 23 LY293558 (5 mg/kg, i.p.) was administered immed
iately before levodopa. In the second set of experiments, rats were treated
daily for 22 days with levodopa and LY293558 (5 mg/kg, twice daily, i.p.).
In the third set of experiments, the effect of LY293558 (5 mg/kg, i.p.) ad
ministration on selective dopamine D-1 (SKF38393, 1.5 mg/kg, s.c.) and D-2
agonist (quinpirole, 0.1 mg/kg, i.p.)-induced rotational behavior after dai
ly levodopa treatment was studied. The duration of the rotational behavior
induced by chronic levodopa decreased by 30% after 22 days. Acute administr
ation of LY293558 on day 23 reversed this effect. The group of animals that
were chronically treated with levodopa and LY293558 did not show the decre
ase in this motor response duration. Chronic levodopa treatment attenuated
the rotational response to the D-1 agonist SKF38393 and increased the respo
nse to the D-2 agonist quinpirole. LY293558 did not reverse the effect of l
evodopa on rotational behavior induced by the D-1 agonist but significantly
reduced the rotational response to the D-2 agonist in levodopa-treated ani
mals by 40%. Our results demonstrate that an AMPA receptor antagonist rever
ses and prevents levodopa-induced motor alterations in parkinsonian rats an
d that this effect on motor fluctuations induced by chronic levodopa is pro
bably due to a modulation of the indirect output pathway of the basal gangl
ia. Synapse 42:40-47, 2001. (C) 2001 Wiley-Liss, Inc.